NuProbe Raises $50 Million for Genomics and Molecular Diagnostics
publication date: Jun 3, 2022
NuProbe Global, with operations in Houston and Shanghai, closed a $50 million funding from China Investors for its genomics and molecular diagnostics business. The company aims to offer the best genomics information to clinicians at a reasonable price. It will use the funds to expand commercial operations, accelerate clinical studies and regulatory submissions for IVD products, and develop new genomics and molecular diagnostics technologies. In 2020, NuProbe merged with CarrierGene Biotech, a Suzhou company developing reproductive diagnostic tests. The latest funding round was co-led by AstraZeneca-CICC Fund, CR-CP Life Science Fund and Panlin Capital. More details....
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.